| 
		Germany's vaccine panel says one COVID shot enough for children
		 Send a link to a friend 
		
		 [May 24, 2022] 
		By Patricia Weiss and Ludwig Burger 
 FRANKFURT (Reuters) - Germany's vaccine 
		advisory panel on Tuesday said one COVID-19 shot was enough for healthy 
		five to 11 year-olds because most of them had already undergone an 
		infection, be it known of undetected.
 
 The view by the panel of 18 appointees known as STIKO contrasts with 
		approval by European Union regulators for a two-shot regimen in that age 
		group. U.S. regulators last week even authorized a third, or booster 
		shot for the group.
 
 "For children we have to assume that the rate of spreading of the 
		infection is the highest. That's why it's reasonable to administer only 
		one vaccination," STIKO panel member Martin Terhardt told a media 
		briefing.
 
 The expert panel's previous view on the age group, published in 
		December, was to limit vaccinations to those at risk of developing 
		severe COVID-19 or those living with an at-risk person, drawing 
		criticism at the time for not keeping up with the of pace of the 
		coronavirus.
 
 Children at risk of developing severe COVID-19 should get three shots 
		and those living with an at-risk person should get two, the expert group 
		added on Tuesday.
 
		[to top of second column] | 
            
			 
            
			Eleven-year-old Chiara receives a dose of the Pfizer-BioNTech 
			vaccine for children against the coronavirus disease (COVID-19) 
			during a vaccination event for children at the Lanxess Arena in 
			Cologne, Germany, December 18, 2021. REUTERS/Thilo Schmuelgen 
            
			
			
			 It did not highlight any 
			disadvantages of giving more shots. Instead it said the risk of 
			heart inflammation from a vaccination appeared to be markedly lower 
			for younger children than in youngsters above 12 years or young 
			adults. An estimated 77.5% of five to 11 year olds in 
			Germany had already had acquired some immunity against the virus 
			either through known and undetected infections or via vaccination, 
			the panel said in a document posted online.
 STIKO said the preferred product was the paediatric version of 
			BioNTech and Pfizer's Comirnaty but Moderna's shot was another 
			option for those six years and older.
 
 (Editing by Madeline Chambers)
 
			[© 2022 Thomson Reuters. All rights 
				reserved.]  This material may not be published, 
			broadcast, rewritten or redistributed.  
			Thompson Reuters is solely responsible for this content. |